← Back to Search

Device

Nano-Pulse Stimulation (NPS) Treated Lesion for Seborrheic Keratosis

N/A
Waitlist Available
Research Sponsored by Pulse Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days post-last treatment
Awards & highlights

Summary

This trial is testing a new treatment called Nano-Pulse Stimulation (NPS) to remove skin lesions in healthy adults. The treatment uses short electrical pulses to clear the lesions without harming nearby skin. The study aims to find the best settings for this treatment and check for any side effects.

Eligible Conditions
  • Skin Lesions
  • Seborrheic Keratosis
  • Benign Skin Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days post-last treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days post-last treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clearance Rate of SK Lesions

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nano-Pulse Stimulation (NPS) Treated LesionExperimental Treatment1 Intervention
Nano-Pulse Stimulation of targeted lesion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nano-Pulse Stimulation (NPS)
2017
N/A
~60

Find a Location

Who is running the clinical trial?

Pulse Biosciences, Inc.Lead Sponsor
9 Previous Clinical Trials
617 Total Patients Enrolled
Richard A Nuccitelli, PhDStudy ChairPulse Biosciences, Inc.
2 Previous Clinical Trials
183 Total Patients Enrolled
~27 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top